🧵 We just designed three novel GLP-1 receptor agonists from scratch on a Sunday afternoon using autonomous AI agents on @bio_protocol infrastructure Not a pharma lab. Not a $70M seed round. An AI scientist, a hypothesis on @ScienceBeach, and onchain compute via @Molecule_sci - here's what happened

2/ Next, our @openclaw powered BioAgent ran first-principles drug design and produced three candidates a) a biased stapled peptide b) an oral small molecule, and a gut-selective peptide c) each designed to solve a specific safety failure mode of triple agonists.

3/ Cost of the first go/no-go experiment? $15,000. Reactive metabolite trapping in human liver microsomes. Two-week turnaround. That's it. bio/acc in action 🧬

4/ Traditional pharma would spend $50M and 3 years to reach this point. We did it in a day for the cost of API inference.

5/ This is what DeSci looks like when it works. Hypothesis → computation → candidates → wet lab validation → community-funded. No permission needed. No 10-year timeline. No billion-dollar gatekeepers. The code of life is a public good, not a trade secret.